Inhibikase Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $26 | $0 |
Gross Profit | -24 | -12 | 13 | -6 |
EBITDA | -11,166 | -15,750 | -12,922 | -5,820 |
EBIT | -11,190 | -15,762 | -12,928 | -5,827 |
Net Income | -9,915 | -13,678 | -12,132 | -5,778 |
Net Change In Cash | 0 | 0 | 26 | 0 |
Free Cash Flow | -5,574 | -4,103 | -5,345 | -4,881 |
Cash | 77,742 | 73,441 | 56,490 | 913 |
Basic Shares | 90,009 | 89,537 | 69,362 | 8,882 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $260 | $123 | $3,100 |
Gross Profit | -26 | -13,357 | 116 | 3,100 |
EBITDA | -27,493 | -19,912 | -18,121 | -14,766 |
EBIT | -27,519 | -20,089 | -18,128 | -14,766 |
Net Income | -27,519 | -19,028 | -17,905 | -14,805 |
Net Change In Cash | 0 | 260 | 123 | 3,100 |
Free Cash Flow | -19,148 | -18,099 | -17,594 | -14,297 |
Cash | 56,490 | 9,165 | 7,188 | 40,750 |
Basic Shares | 23,712 | 5,333 | 4,201 | 3,034 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.11 |
2025-03-31 | -$0.15 |
2024-12-31 | -$0.17 |
2024-09-30 | -$0.65 |
